Skip to main content
Top
Published in: BMC Ophthalmology 1/2017

Open Access 01-12-2017 | Research article

Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study

Authors: Mari Elshout, Carroll A. Webers, Margriet I. van der Reis, Yvonne de Jong-Hesse, Jan S. Schouten

Published in: BMC Ophthalmology | Issue 1/2017

Login to get access

Abstract

Background

Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in discussing prognosis and treatment options with patients and to support cost-effectiveness studies.

Methods

First, we performed a literature search in PubMed, Embase, and Cochrane. We included randomized clinical trials and prospective observational studies reporting visual acuity (VA) in non-treated patients, 24 studies in total. We integrated VA data using best fit on Lineweaver-Burke plots and modelled with non-linear regression using reciprocal terms. Second, we performed a quality-of-life (QoL) study in nAMD patients. We measured VA with Radner reading charts and QoL with the Health Utilities Index issue 3 (HUI-3) questionnaire in 184 participants. We studied the relation VA-QoL with linear regression. Third, with Monte Carlo simulation, we integrated the VA model from the literature review and the relation VA-QoL from the QoL study.

Results

Visual acuity was 0.4 and 0.07 after 5 years in the better-seeing, and worse-seeing eye, respectively. After 4.3 years, VA was <0.5 in the better-seeing eye; <0.3 after 7 years; 0.05 after 17 years. QoL score decreased from 0.6 to 0.45 after 10 years.

Conclusions

The natural course of nAMD in both eyes needs to be considered when informing patients. Visual acuity in the best eye decreases to below 0.5 in 4.3 years. This affects QoL significantly.
Appendix
Available only for authorised users
Literature
1.
go back to reference Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116(4):514–20.CrossRefPubMed Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116(4):514–20.CrossRefPubMed
2.
go back to reference Schmier JK, Hulme-Lowe CK. Cost-effectiveness models in age-related macular degeneration: issues and challenges. PharmacoEconomics. 2016;34(3):259–72.CrossRefPubMed Schmier JK, Hulme-Lowe CK. Cost-effectiveness models in age-related macular degeneration: issues and challenges. PharmacoEconomics. 2016;34(3):259–72.CrossRefPubMed
3.
go back to reference Ghosh W, Wickstead R, Claxton L, Kusel J, Taylor M, Fleetwood K, Pulikottil-Jacob R. The cost-effectiveness of ranibizumab treat and extend regimen versus aflibercept in the UK. Adv Ther. 2016;33(9):1660–76.CrossRefPubMed Ghosh W, Wickstead R, Claxton L, Kusel J, Taylor M, Fleetwood K, Pulikottil-Jacob R. The cost-effectiveness of ranibizumab treat and extend regimen versus aflibercept in the UK. Adv Ther. 2016;33(9):1660–76.CrossRefPubMed
4.
go back to reference Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009;116(10):1901–7.CrossRefPubMed Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009;116(10):1901–7.CrossRefPubMed
5.
go back to reference Shah AR, Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2007;143(1):83–9.CrossRefPubMed Shah AR, Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2007;143(1):83–9.CrossRefPubMed
6.
go back to reference Radner W, Willinger U, Obermayer W, Mudrich C, Velikay-Parel M, Eisenwort B. A new reading chart for simultaneous determination of reading vision and reading speed. Klin Monatsbl Augenheilkd. 1998;213(3):174–81.CrossRefPubMed Radner W, Willinger U, Obermayer W, Mudrich C, Velikay-Parel M, Eisenwort B. A new reading chart for simultaneous determination of reading vision and reading speed. Klin Monatsbl Augenheilkd. 1998;213(3):174–81.CrossRefPubMed
7.
go back to reference Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–28.CrossRefPubMed Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–28.CrossRefPubMed
8.
go back to reference Elshout M, van der Reis MI, de Jong-Hesse Y, Webers CA, Schouten JS. Distinguishing between better and worse visual acuity by studying the correlation with quality of life in neovascular age-related macular degeneration. Ophthalmology. 2016;123(11):2408–12.CrossRefPubMed Elshout M, van der Reis MI, de Jong-Hesse Y, Webers CA, Schouten JS. Distinguishing between better and worse visual acuity by studying the correlation with quality of life in neovascular age-related macular degeneration. Ophthalmology. 2016;123(11):2408–12.CrossRefPubMed
9.
go back to reference Elshout M, van der Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1911–20.CrossRefPubMed Elshout M, van der Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1911–20.CrossRefPubMed
10.
go back to reference van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health. 2010;13(4):358–67.CrossRefPubMed van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health. 2010;13(4):358–67.CrossRefPubMed
11.
go back to reference Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.CrossRefPubMed Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.CrossRefPubMed
12.
go back to reference Medeiros FA, Gracitelli CP, Boer ER, Weinreb RN, Zangwill LM, Rosen PN. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122(2):293–301.CrossRefPubMed Medeiros FA, Gracitelli CP, Boer ER, Weinreb RN, Zangwill LM, Rosen PN. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology. 2015;122(2):293–301.CrossRefPubMed
13.
go back to reference Bowker SL, Pohar SL, Johnson JA. A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual Life Outcomes. 2006;4:17.CrossRefPubMedPubMedCentral Bowker SL, Pohar SL, Johnson JA. A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health Qual Life Outcomes. 2006;4:17.CrossRefPubMedPubMedCentral
14.
15.
go back to reference Arnold J, Barbazetto I, Birngruber R, Blumenkranz MS, Bressler SB, Bressler NM, Donati G, Fish GE, Gragoudas ES, Harvey P, et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119(2):198–207. Arnold J, Barbazetto I, Birngruber R, Blumenkranz MS, Bressler SB, Bressler NM, Donati G, Fish GE, Gragoudas ES, Harvey P, et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119(2):198–207.
16.
go back to reference Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136(3):407–18.CrossRefPubMed Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136(3):407–18.CrossRefPubMed
17.
go back to reference Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246–52.CrossRefPubMed Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246–52.CrossRefPubMed
18.
go back to reference Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol. 1988;106(11):1537–42.CrossRefPubMed Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol. 1988;106(11):1537–42.CrossRefPubMed
19.
go back to reference Bressler. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1996;114(4):400–12.CrossRef Bressler. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1996;114(4):400–12.CrossRef
20.
go back to reference Cardillo-Piccolino F, Ghiglione D, Borgia L, Zingirian M. New occult choroidal vessels in age-related macular degeneration. J Fr Ophtalmol. 1989;12(12):869–76.PubMed Cardillo-Piccolino F, Ghiglione D, Borgia L, Zingirian M. New occult choroidal vessels in age-related macular degeneration. J Fr Ophtalmol. 1989;12(12):869–76.PubMed
21.
go back to reference Eter N, Schuller H, Spitznas M. Radiotherapy for age-related macular degeneration: is there a benefit for classic CNV? Int Ophthalmol. 2001;24(1):13–9.CrossRefPubMed Eter N, Schuller H, Spitznas M. Radiotherapy for age-related macular degeneration: is there a benefit for classic CNV? Int Ophthalmol. 2001;24(1):13–9.CrossRefPubMed
22.
go back to reference Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–16.CrossRefPubMed Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–16.CrossRefPubMed
23.
go back to reference Gustavsson C, Agardh E. Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. Acta Ophthalmol Scand. 2005;83(2):148–53.CrossRefPubMed Gustavsson C, Agardh E. Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. Acta Ophthalmol Scand. 2005;83(2):148–53.CrossRefPubMed
24.
go back to reference Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology. 2005;112(4):567–73.CrossRefPubMed Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology. 2005;112(4):567–73.CrossRefPubMed
25.
go back to reference Kaiser PK. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin. 2009;25(8):1853–60.CrossRefPubMed Kaiser PK. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin. 2009;25(8):1853–60.CrossRefPubMed
26.
go back to reference Kobayashi H, Kobayashi K. Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol. 2000;130(5):617–35.CrossRefPubMed Kobayashi H, Kobayashi K. Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol. 2000;130(5):617–35.CrossRefPubMed
27.
go back to reference Krebs I, Stolba U, Glittenberg C, Seyeddain O, Benesch T, Binder S. Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245(3):376–84.CrossRefPubMed Krebs I, Stolba U, Glittenberg C, Seyeddain O, Benesch T, Binder S. Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245(3):376–84.CrossRefPubMed
28.
go back to reference Myint K, Armbrecht AM, Mon S, Dhillon B. Transpupillary thermotherapy for the treatment of occult CNV in age-related macular degeneration: a prospective randomized controlled pilot study. Acta Ophthalmol Scand. 2006;84(3):328–32.CrossRefPubMed Myint K, Armbrecht AM, Mon S, Dhillon B. Transpupillary thermotherapy for the treatment of occult CNV in age-related macular degeneration: a prospective randomized controlled pilot study. Acta Ophthalmol Scand. 2006;84(3):328–32.CrossRefPubMed
29.
go back to reference Pece A, Bolognesi G, Introini U, Pacelli G, Calori G, Brancato R. Indocyanine green angiography of well-defined plaque choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 2000;118(5):630–4.CrossRefPubMed Pece A, Bolognesi G, Introini U, Pacelli G, Calori G, Brancato R. Indocyanine green angiography of well-defined plaque choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 2000;118(5):630–4.CrossRefPubMed
30.
go back to reference Soubrane G, Coscas G, Francais C, Koenig F. Occult subretinal new vessels in age-related macular degeneration. Natural History and early laser treatment. Ophthalmology. 1990;97(5):649–57.CrossRefPubMed Soubrane G, Coscas G, Francais C, Koenig F. Occult subretinal new vessels in age-related macular degeneration. Natural History and early laser treatment. Ophthalmology. 1990;97(5):649–57.CrossRefPubMed
31.
go back to reference Tholen AM, Meister A, Bernasconi PP, Messmer EP. Radiotherapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Klin Monatsbl Augenheilkd. 2000;216(2):112–5.CrossRefPubMed Tholen AM, Meister A, Bernasconi PP, Messmer EP. Radiotherapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Klin Monatsbl Augenheilkd. 2000;216(2):112–5.CrossRefPubMed
32.
go back to reference Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123(4):448–57.CrossRefPubMed Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123(4):448–57.CrossRefPubMed
33.
go back to reference Schneider U, Gelisken F, Inhoffen W. Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand. 2005;83(2):141–7.CrossRefPubMed Schneider U, Gelisken F, Inhoffen W. Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmol Scand. 2005;83(2):141–7.CrossRefPubMed
34.
go back to reference D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110(12):2372–83. discussin 2384-2375CrossRefPubMed D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110(12):2372–83. discussin 2384-2375CrossRefPubMed
35.
go back to reference Russell SR, Hudson HL, Jerdan JA. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. Surv Ophthalmol. 2007;52(Suppl 1):S79–90.CrossRefPubMed Russell SR, Hudson HL, Jerdan JA. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. Surv Ophthalmol. 2007;52(Suppl 1):S79–90.CrossRefPubMed
36.
go back to reference Group MPS. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109(9):1232–41.CrossRef Group MPS. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109(9):1232–41.CrossRef
37.
go back to reference Mandai M, Takahashi M, Miyamoto H, Hiroshiba N, Kimura H, Ogura Y, Honda Y, Sasai K. Long-term outcome after radiation therapy for subfoveal choroidal neovascularization associated with age-related macular degeneration. Jpn J Ophthalmol. 2000;44(5):530–7.CrossRefPubMed Mandai M, Takahashi M, Miyamoto H, Hiroshiba N, Kimura H, Ogura Y, Honda Y, Sasai K. Long-term outcome after radiation therapy for subfoveal choroidal neovascularization associated with age-related macular degeneration. Jpn J Ophthalmol. 2000;44(5):530–7.CrossRefPubMed
38.
go back to reference Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: a randomized clinical trial. Am J Ophthalmol. 2002;133(4):521–9.CrossRefPubMed Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: a randomized clinical trial. Am J Ophthalmol. 2002;133(4):521–9.CrossRefPubMed
39.
go back to reference Behrendt C. Visual acuity and its decrease in classic neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2004;11(5):359–67.CrossRefPubMed Behrendt C. Visual acuity and its decrease in classic neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2004;11(5):359–67.CrossRefPubMed
Metadata
Title
Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study
Authors
Mari Elshout
Carroll A. Webers
Margriet I. van der Reis
Yvonne de Jong-Hesse
Jan S. Schouten
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-017-0514-3

Other articles of this Issue 1/2017

BMC Ophthalmology 1/2017 Go to the issue